Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00
CLDI.WS
CLDI.WS was delisted on the 17th of October, 2024.
16 hedge funds and large institutions have $385K invested in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 3 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% less capital invested
Capital invested by funds: $386K → $385K (-$837)
6% less funds holding
Funds holding: 17 → 16 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$952 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$8 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.03K |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$261 |
| 3 |
SOA
Sea Otter Advisors
Miami,
Florida
|
-$244 |
| 4 |
CAC
Cowen and Company
New York
|
-$6 |
CLDI.WS Hedge Fund Activity: Q1 2024 in Review
16 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) for Q1 2024, worth a combined $385K — down 0.22% from $386K a quarter earlier.
Fund positioning in CLDI.WS was balanced in Q1 2024: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $952. The largest seller was Bank of Montreal, exiting entirely with an estimated $2.03K sold.
- 16 institutional investors held Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 (CLDI.WS) as of Q1 2024, down from 17 in Q4 2023.
- Funds reported $385K of Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 stock for Q1 2024, down 0.22% quarter-over-quarter.
- 3 funds opened new Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 positions in Q1 2024 and 3 closed out, a net change of 0 holders.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 buyer in Q1 2024 was Citadel Advisors, an estimated $952 added.
- The largest Calidi Biotherapeutics, Inc. Redeemable Warrants, each whole warrant exercisable for 1/10th of a share of Common Stock at an exercise price of $115.00 seller in Q1 2024 was Bank of Montreal, an estimated $2.03K sold.
Based on aggregated 13F filings for Q1 2024.